The French prosecutor found no connection between the alleged switching and Teva's plant in Sens.
After a difficult month, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) can put behind it the unfortunate affair of the switching of drug packaging in France. After the French health authorities found a few days ago that no fatalities were caused by the switch (contrary to initial suspicions), the preliminary investigation by the prosecutor in Paris has also reached conclusions favorable to Teva.
The prosecutor's investigation found no trace of Teva's sedative zopiclone in its diuretic furosemide for treating edema. It was therefore concluded that there was no connection between the Teva's production plant in Sens, where the furosemide in 40 mg doses was packed, and the apparent switching of the tablets, as reported by a pharmacist in Saint-Malo.
Published by Globes [online], Israel business news - www.globes-online.com - on July 1, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013